Medical College of Wisconsin bone marrow transplant and cellular therapy center
BMT Core- Medical College of Wisconsin
This program offers a dual-target CAR T-cell therapy against CD19 and CD20 for people with relapsed or hard-to-treat mantle cell lymphoma, including those with 17p deletions or TP53 mutations.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical College of Wisconsin NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project ID | NIH-11166540 on NIH RePORTER |
What this research studies
The Medical College of Wisconsin runs a transplant and cellular therapy center that enrolls patients in BMT CTN trials and conducts a trial of a bispecific CAR T-cell product called CAR20.19. CAR20.19 is engineered to target two B-cell proteins (CD19 and CD20) and built on an early dose-finding study that showed a safe dose and initial signs of benefit. Patients would receive preparative (lymphodepleting) chemotherapy followed by infusion of their engineered T cells and close follow-up for side effects and response. The center collects high-quality clinical data and biospecimens as part of the trial and contributes to broader transplant and cellular-therapy research efforts.
Who could benefit from this research
Good fit: Adults with relapsed or refractory mantle cell lymphoma who have received prior therapies and meet CAR T-cell treatment and transplant eligibility, including those with 17p deletion or TP53 mutations, are the most likely candidates.
Not a fit: People with other cancer types, those whose tumors lack CD19 or CD20, or patients who cannot tolerate lymphodepleting chemotherapy or CAR T-related toxicities are unlikely to benefit.
Why it matters
Potential benefit: If successful, the dual-target CAR T approach could increase remission rates and extend progression-free and overall survival for people with relapsed or refractory mantle cell lymphoma, especially those with high-risk genetic features.
How similar studies have performed: An early Phase 1 dose-escalation study published in Nature Medicine reported a safe dose and preliminary safety and efficacy for this dual-target CAR, so the approach is promising but still being tested in later-phase studies.
Where this research is happening
Milwaukee, United States
- Medical College of Wisconsin — Milwaukee, United States (Active)
Researchers
- Principal investigator: Shah, Nirav — Medical College of Wisconsin
- Study coordinator: Shah, Nirav
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.